NHMRC Interim Report on Puberty Blockers: Implications for Clinical Practice and Litigation
The NHMRC’s preliminary report, which appears to offer a conditional recommendation in support of puberty blockers for young people experiencing either gender dysphoria (where a medical condition may be present) or gender incongruence (where a medical disorder may not be present), raises important questions about the future of clinical practice and litigation in this area.
One concern is that the NHMRC’s position may make it considerably more difficult to pursue litigation involving practitioners who have adopted a gender-affirming medicalisation approach to the treatment of young people. Clinicians may seek to rely on the NHMRC’s recommendation as evidence that their prescribing decisions were consistent with an accepted national position.
However, I find it difficult to reconcile the conditional endorsement of these medications with concerns about their potentially serious adverse effects, uncertain long-term consequences and the extent to which some interventions may have lasting implications, particularly when they are prescribed to young people who may not have an underlying medical or psychiatric disorder.
Australian legal precedent highlights the importance of appropriate, evidence-based and proportionate medical treatment. Decisions of the Family Court of Australia have emphasised the significance of establishing an underlying medical condition, undertaking a proper diagnostic assessment and ensuring that proposed interventions are legitimate treatments directed towards an established pathology or psychiatric disorder. The therapeutic justification for an intervention, together with its proportionality to the intended purpose, is also central to these considerations.
Applied to gender-related medical interventions in young people, these principles require clinicians to demonstrate a clear diagnostic formulation, consider relevant differential diagnoses, identify an appropriately established treatment rationale, and carefully balance anticipated benefits against potential adverse effects. Equally important are informed consent and a careful assessment of the young person’s capacity to understand the nature, consequences and longer-term implications of the proposed intervention.
An NHMRC recommendation, even if conditional, should not be regarded as a substitute for individual clinical judgement, sound diagnostic practice or the clinician’s duty to ensure that treatment is necessary, proportionate and in the patient’s best interests.
Philip Morris AM